Form 4: BioCardia Director Acquires Shares and Warrants in Private Placement

Director Andrew Scott Blank acquired shares and warrants of BioCardia, Inc. through a private placement on April 23, 2025.

Summary

• On April 23, 2025, Andrew Scott Blank, a director of BioCardia, Inc., acquired 131,233 shares of common stock at a price of $1.905 per share through a private placement.
• In addition to the shares, Blank also received warrants to purchase 131,233 shares of common stock at an exercise price of $1.905, expiring on April 23, 2030.
• Following the transaction, Blank directly owns 9,812 shares and indirectly owns 265,957 shares through the Andy Blank Revocable Living Trust.
• The warrants are also held indirectly through the Andy Blank Revocable Living Trust, totaling 242,233 warrants.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing an insider transaction. The director's participation in the private placement could be viewed slightly positively.

Positives

• The director's participation in the private placement could be seen as a sign of confidence in the company's future prospects.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about management's view of the company's prospects. Private placements are a common way for companies, especially smaller ones like BioCardia, to raise capital.

Stakeholder Impact

• Shareholders may view the director's investment as a positive signal.
• The private placement could dilute existing shareholders' ownership.

Key Dates

Keywords

BioCardia, BCDA, director, Andrew Scott Blank, private placement, common stock, warrants, beneficial ownership, Form 4